Artelo Biosciences Stock News

Artelo Biosciences Inc. (NASDAQ:ARTL) shares, rose in value on Wednesday, 03/09/22, with the stock price up by 4.21% to the previous day’s close as strong demand from buyers drove the stock to $0.43. Actively observing the price movement in the last trading, the stock closed the session at $0.41, falling within a range of $0.4105 … Artelo Biosciences Inc. (NASDAQ: ARTL) Surged 4.21%, So What Now? Read More »

Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM ) rose 420% to $7.90 in pre-market trading. Sunshine Biopharma, last month, priced its 1.88 million unit uplisting to Nasdaq at $4.25 per unit. TC Biopharm (Holdings) Plc (NASDAQ: TCBP ) rose 90% to $1.84 in pre-market trading. TC BioPharm, on Tuesday, disclosed positive Phase 1b/2a data in late-stage Acute Myeloid Leukemia patients treated with allogeneic gamma delta T cells. Direct Digital Holdings, Inc. (NASDAQ: DRCT ) rose 63.3% to $1.96 in pre-market trading. Benchmark initiated coverage on Direct Digital with a Buy rating and announced a price target of $8. ECMOHO Limited (NASDAQ: MOHO ) shares rose 35.9% to $0.2901 in pre-market trading. Ecoark Holdings, Inc. (NASDAQ: ZEST ) rose 33.1% to $4.06 in pre-market trading after the company reported successful drilling of Louisiana oil well. Artelo Biosciences, Inc. (NASDAQ: ARTL ) rose 25.7% to $0.5170 in pre-market trading. Artelo Biosciences, last week, received a Notice of Allowance for method-of-use patent in the United States for ART12.11, a proprietary cocrystal of cannabidiol.

Artelo Biosciences (ARTL): FQ1 GAAP EPS of -$0.08 misses by $0.02.As of November 30, 2021, the company had ~$26.4M in cash and marketable securities, compared to $10.07M as of August

HC Wainwright reaffirmed their buy rating on shares of Artelo Biosciences (NASDAQ:ARTL) in a research report released on Tuesday, TipRanks reports. The brokerage currently has a $4.00 price target on the stock. Other equities research analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Artelo Biosciences from a sell []

$26.8 Million in Cash and Marketable Securities as of November 15, 2021, Expected to Support Operations Well Into 2023 $26.8 Million in Cash and Marketable Securities as of November 15, 2021, Expected to Support Operations Well Into 2023

Renaissance Technologies LLC purchased a new position in Artelo Biosciences, Inc. (NASDAQ:ARTL) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 556,738 shares of the companys stock, valued at approximately $663,000. Renaissance Technologies LLC owned approximately 2.27% of Artelo Biosciences at []

Analysts expect that Artelo Biosciences, Inc. (NASDAQ:ARTL) will post earnings of ($0.10) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Artelo Biosciences’ earnings. Artelo Biosciences reported earnings of ($0.20) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 50%. […]